anti-GPRC5D bispecific T cell engager

Anti-GPRC5D bispecific T-cell engagers (TCEs) are a class of immunotherapy designed to treat multiple myeloma by simultaneously binding to G protein-coupled receptor class C group 5 member D (GPRC5D) on malignant plasma cells and the CD3 receptor on T cells. This dual binding facilitates the recruitment and activation of T cells, leading to the direct lysis of the GPRC5D-expressing tumor cells. GPRC5D is highly and specifically expressed on plasma cells, making it an ideal target for multiple myeloma therapies, particularly in patients who have relapsed or are refractory to other treatments like BCMA-targeted therapies. Notable examples in this class include talquetamab and forimtamig.

Other names

anti-GPRC5D TCEanti-GPRC-5D TCEanti-GPRC 5D TCEGPRC5D bispecific antibodyGPRC-5D bispecific antibodyGPRC 5D bispecific antibodyGPRC5D x CD3 bispecific antibodyGPRC-5D x CD3 bispecific antibodyGPRC 5D x CD3 bispecific antibodyanti-GPRC5D bispecific T cell engageranti-GPRC-5D bispecific T cell engageranti-GPRC 5D bispecific T cell engager